Table 6.
Linear regression analysis of factors influencing MRI-PDFF increment during follow-up.
| Factors | Univariate | Multivariate | ||
|---|---|---|---|---|
| β (95% CI) | p-value | β (95% CI) | p-value | |
| △BMI, kg/m2 | 0.76 (0.20–1.32) | 0.008 | 0.14 (−0.49 to 0.78) | 0.65 |
| △Waist circumstance, cm | 0.84 (0.55–1.13) | <0.001 | 0.35 (0.08–0.63) | 0.013 |
| △Alanine aminotransferase, U/l | 0.03 (0.01–0.05) | 0.004 | 0.01 (−0.01–0.03) | 0.16 |
| △Total cholesterol, mmol/l | 0.59 (−0.11 to 1.28) | 0.10 | ||
| △Triglycerides, mmol/l | 0.49 (0.09–2.05) | 0.033 | 0.24 (−0.58 to 1.06) | 0.16 |
| △HDL-C, mmol/l | 1.63 (−1.52 to 4.78) | 0.31 | ||
| △LDL-C, mmol/l | 0.92 (−0.05 to 1.89) | 0.35 | ||
| △Fasting blood glucose, mmol/l | 0.23 (−0.33 to 0.79) | 0.42 | ||
| △Fasting insulin, μU/ml | −0.01 (−0.04 to 0.04) | 0.96 | ||
| △HOMA-IR | 0.32 (−0.22 to 0.85) | 0.23 | ||
| △Uric acid, μmol/l | 0.01 (0.001–0.02) | 0.026 | 0.01 (−0.01 to 0.02) | 0.60 |
| △CAP, dB/m | 0.09 (0.06–0.11) | <0.001 | 0.10 (0.06–0.13) | <0.001 |
| △LSM, kPa | −0.05 (−0.94 to 0.85) | 0.92 | ||
BMI, body mass index; CAP, controlled attenuation parameter; CI, confidence interval; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein-cholesterol; LSM, liver stiffness measurement; MRI-PDFF, magnetic resonance imaging-based proton density fat fraction.